Chloroquine-Modified Hydroxyethyl Starch as a Polymeric Drug for Cancer Therapy

Richard Sleightholm, Bin Yang, Fei Yu, Ying Xie, David Oupicky

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hydroxyethyl starch (HES) is a clinically used polysaccharide colloidal plasma volume expander. The goal of this study was to synthesize HES modified with hydroxychloroquine (HCQ) as a novel polymeric drug with the ability to inhibit the invasive character of pancreatic cancer (PC) cells. HES was conjugated with HCQ using a simple carbonyldiimidazole coupling to prepare Chloroquine-modified HES (CQ-HES). CQ-HES with various degrees of HCQ substitution were synthesized and characterized. Atomic force microscopy was used to demonstrate a pH-dependent assembly of CQ-HES into well-defined nanoparticles. In vitro studies in multiple PC cell lines showed CQ-HES to have a similar toxicity profile as HCQ. Confocal microscopy revealed the propensity of CQ-HES to localize to lysosomes and mechanistic studies confirmed the ability of CQ-HES to inhibit autophagy in PC cells. Further studies demonstrated a greatly enhanced ability of CQ-HES to inhibit the migration and invasion of PC cells when compared with HCQ. The enhanced inhibitory actions of CQ-HES compared to HCQ appeared to arise in part from the increased inhibition of ERK and Akt phosphorylation. We found no significant HCQ release from CQ-HES, which confirmed that the observed activity was due to the action of CQ-HES as a polymeric drug. Due to its promising ability to block cancer cell invasion and the ability to form nanoparticles, CQ-HES has the potential as a drug delivery platform suitable for future development with chemotherapeutics to establish novel antimetastatic treatments.

Original languageEnglish (US)
Pages (from-to)2247-2257
Number of pages11
JournalBiomacromolecules
Volume18
Issue number8
DOIs
StatePublished - Aug 14 2017

Fingerprint

Chloroquine
Starch
Hydroxychloroquine
Cells
Pharmaceutical Preparations
Nanoparticles
Phosphorylation
Confocal microscopy
Polysaccharides
Drug delivery
Toxicity
Atomic force microscopy
Substitution reactions
Plasmas
Plasma Substitutes

ASJC Scopus subject areas

  • Bioengineering
  • Biomaterials
  • Polymers and Plastics
  • Materials Chemistry

Cite this

Chloroquine-Modified Hydroxyethyl Starch as a Polymeric Drug for Cancer Therapy. / Sleightholm, Richard; Yang, Bin; Yu, Fei; Xie, Ying; Oupicky, David.

In: Biomacromolecules, Vol. 18, No. 8, 14.08.2017, p. 2247-2257.

Research output: Contribution to journalArticle

Sleightholm, Richard ; Yang, Bin ; Yu, Fei ; Xie, Ying ; Oupicky, David. / Chloroquine-Modified Hydroxyethyl Starch as a Polymeric Drug for Cancer Therapy. In: Biomacromolecules. 2017 ; Vol. 18, No. 8. pp. 2247-2257.
@article{7fbace7ec8bc4c939a185894b4b7e046,
title = "Chloroquine-Modified Hydroxyethyl Starch as a Polymeric Drug for Cancer Therapy",
abstract = "Hydroxyethyl starch (HES) is a clinically used polysaccharide colloidal plasma volume expander. The goal of this study was to synthesize HES modified with hydroxychloroquine (HCQ) as a novel polymeric drug with the ability to inhibit the invasive character of pancreatic cancer (PC) cells. HES was conjugated with HCQ using a simple carbonyldiimidazole coupling to prepare Chloroquine-modified HES (CQ-HES). CQ-HES with various degrees of HCQ substitution were synthesized and characterized. Atomic force microscopy was used to demonstrate a pH-dependent assembly of CQ-HES into well-defined nanoparticles. In vitro studies in multiple PC cell lines showed CQ-HES to have a similar toxicity profile as HCQ. Confocal microscopy revealed the propensity of CQ-HES to localize to lysosomes and mechanistic studies confirmed the ability of CQ-HES to inhibit autophagy in PC cells. Further studies demonstrated a greatly enhanced ability of CQ-HES to inhibit the migration and invasion of PC cells when compared with HCQ. The enhanced inhibitory actions of CQ-HES compared to HCQ appeared to arise in part from the increased inhibition of ERK and Akt phosphorylation. We found no significant HCQ release from CQ-HES, which confirmed that the observed activity was due to the action of CQ-HES as a polymeric drug. Due to its promising ability to block cancer cell invasion and the ability to form nanoparticles, CQ-HES has the potential as a drug delivery platform suitable for future development with chemotherapeutics to establish novel antimetastatic treatments.",
author = "Richard Sleightholm and Bin Yang and Fei Yu and Ying Xie and David Oupicky",
year = "2017",
month = "8",
day = "14",
doi = "10.1021/acs.biomac.7b00023",
language = "English (US)",
volume = "18",
pages = "2247--2257",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Chloroquine-Modified Hydroxyethyl Starch as a Polymeric Drug for Cancer Therapy

AU - Sleightholm, Richard

AU - Yang, Bin

AU - Yu, Fei

AU - Xie, Ying

AU - Oupicky, David

PY - 2017/8/14

Y1 - 2017/8/14

N2 - Hydroxyethyl starch (HES) is a clinically used polysaccharide colloidal plasma volume expander. The goal of this study was to synthesize HES modified with hydroxychloroquine (HCQ) as a novel polymeric drug with the ability to inhibit the invasive character of pancreatic cancer (PC) cells. HES was conjugated with HCQ using a simple carbonyldiimidazole coupling to prepare Chloroquine-modified HES (CQ-HES). CQ-HES with various degrees of HCQ substitution were synthesized and characterized. Atomic force microscopy was used to demonstrate a pH-dependent assembly of CQ-HES into well-defined nanoparticles. In vitro studies in multiple PC cell lines showed CQ-HES to have a similar toxicity profile as HCQ. Confocal microscopy revealed the propensity of CQ-HES to localize to lysosomes and mechanistic studies confirmed the ability of CQ-HES to inhibit autophagy in PC cells. Further studies demonstrated a greatly enhanced ability of CQ-HES to inhibit the migration and invasion of PC cells when compared with HCQ. The enhanced inhibitory actions of CQ-HES compared to HCQ appeared to arise in part from the increased inhibition of ERK and Akt phosphorylation. We found no significant HCQ release from CQ-HES, which confirmed that the observed activity was due to the action of CQ-HES as a polymeric drug. Due to its promising ability to block cancer cell invasion and the ability to form nanoparticles, CQ-HES has the potential as a drug delivery platform suitable for future development with chemotherapeutics to establish novel antimetastatic treatments.

AB - Hydroxyethyl starch (HES) is a clinically used polysaccharide colloidal plasma volume expander. The goal of this study was to synthesize HES modified with hydroxychloroquine (HCQ) as a novel polymeric drug with the ability to inhibit the invasive character of pancreatic cancer (PC) cells. HES was conjugated with HCQ using a simple carbonyldiimidazole coupling to prepare Chloroquine-modified HES (CQ-HES). CQ-HES with various degrees of HCQ substitution were synthesized and characterized. Atomic force microscopy was used to demonstrate a pH-dependent assembly of CQ-HES into well-defined nanoparticles. In vitro studies in multiple PC cell lines showed CQ-HES to have a similar toxicity profile as HCQ. Confocal microscopy revealed the propensity of CQ-HES to localize to lysosomes and mechanistic studies confirmed the ability of CQ-HES to inhibit autophagy in PC cells. Further studies demonstrated a greatly enhanced ability of CQ-HES to inhibit the migration and invasion of PC cells when compared with HCQ. The enhanced inhibitory actions of CQ-HES compared to HCQ appeared to arise in part from the increased inhibition of ERK and Akt phosphorylation. We found no significant HCQ release from CQ-HES, which confirmed that the observed activity was due to the action of CQ-HES as a polymeric drug. Due to its promising ability to block cancer cell invasion and the ability to form nanoparticles, CQ-HES has the potential as a drug delivery platform suitable for future development with chemotherapeutics to establish novel antimetastatic treatments.

UR - http://www.scopus.com/inward/record.url?scp=85027334089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027334089&partnerID=8YFLogxK

U2 - 10.1021/acs.biomac.7b00023

DO - 10.1021/acs.biomac.7b00023

M3 - Article

VL - 18

SP - 2247

EP - 2257

JO - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 8

ER -